申请人:Duquesne University of the Holy Ghost
公开号:US05571933A1
公开(公告)日:1996-11-05
This invention discloses compounds useful as steroid inhibitors. The compounds comprise the formula (5) ##STR1## wherein (a) R.sub.1 is hydrogen and R.sub.2 is selected from the group consisting of SO.sub.2 CF.sub.3, SO.sub.2 NH.sub.2, SO.sub.2 (C.sub.1 -C.sub.6 -alkyl), COCF.sub.3, CONH.sub.2, CO(C.sub.1-C.sub.6 -alkyl); and (b) the ring system ABCD is a steroid nucleus selected from the group consisting of estrone, dehydroepiandrosterone, estradiol, estradiolester, pregnenolone, substituted estrones, substituted dehydroepiandrosterone, substituted estradiols, substituted estradiolesters and substituted pregnenolone. Preferably the steroid nucleus is selected from the group consisting of estrone, dehydropeiandrosterone and pregnenolone. The invention also discloses methods of treating a patient therapeutically and prophylactically for estrogen dependent diseases with the compounds of this invention.
本发明揭示了作为类固醇抑制剂有用的化合物。该化合物包括公式(5)##STR1##其中(a)R.sub.1为氢,R.sub.2选择自SO.sub.2CF.sub.3,SO.sub.2NH.sub.2,SO.sub.2(C.sub.1-C.sub.6-烷基),COCF.sub.3,CONH.sub.2,CO(C.sub.1-C.sub.6-烷基)的组合;(b)环系ABCD是从雌甾酮,去氢表雄酮,雌二醇,酯化的雌二醇,孕酮,取代的雌甾酮,取代的去氢表雄酮,取代的雌二醇,取代的酯化雌二醇和取代的孕酮中选择的类固醇核。优选的类固醇核选择自雌甾酮,去氢表雄酮和孕酮的组合。本发明还揭示了使用该化合物治疗患有雌激素依赖性疾病的患者的治疗和预防方法。